Schedule 13G ownership disclosure
Zentalis Pharmaceuticals, Inc.
Security class unavailable · CUSIP: 98943L107
Event date: 2021-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 4,349,279
- Percent of class
- 9.6000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-22-001676
- Form type
- SC 13G
- Filer
- Matrix Capital Management Company, LP
- CIK
- CIK 1410830
- Filed
- Feb 14, 2022
- Reporting period
- Dec 31, 2021
- Description
- Schedule 13G beneficial ownership